Recordati Rare Diseases has established a direct presence in the key markets across all continents. The Italian rare diseases and orphan drug specialists now have local Recordati Rare Diseases companies active in the US, Latin America, Europe, MENA (Middle East and North Africa) and Asia Pacific.
Andrea Recordati, CEO of Recordati, said: “In the last few years we set up our Recordati Rare Diseases subsidiaries in countries such as Mexico, Colombia, Brazil, Canada, Australia and Japan.”
“Recordati Rare Diseases is now present in over 50 countries including several local partnerships and direct exports. We ensure worldwide availability and timely supply of our rare disease products from our Nanterre (France) dedicated plant,” Recordati added.
Several companies formerly operating under the name of Orphan Europe were recently renamed Recordati Rare Diseases, which is today the global brand of Recordati’s organisation dedicated to treatments for rare diseases and orphan drugs.
Orphan Europe, founded in 1990, pioneered the development of orphan drugs in Europe and became part of Recordati in 2007.
The claim “Focused on the few” in the logo signals Recordati Rare Diseases’ belief that every single patient should have the best possible treatment. To this end, Recordati Rare Diseases works across the world with patients and their families, patient groups, scientific researchers, academics, key opinion leaders, healthcare professionals, policymakers and regulators.
Recordati Rare Diseases is committed to improving the diagnosis and management of rare diseases also through focused educational work and the activity of the Recordati Rare Diseases Foundation.
